Ligand Pharmaceuticals Incorporated (LGND)

Ligand Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	208.9	72.31	22.95	45.01	19.52	47.62
Short-Term Investments	-	183.86	147.36	166.86	321.59	363.57
Cash & Short-Term Investments	208.9	256.17	170.31	211.87	341.11	411.19
Cash Growth	-32.74%	50.41%	-19.62%	-37.89%	-17.04%	-61.57%
Accounts Receivable	38.49	38.38	32.92	30.42	85.45	56.85
Other Receivables	4.34	4.07	6.4	4.61	6.19	2.22
Receivables	42.83	42.45	39.31	35.04	91.65	59.06
Inventory	14.61	14.11	23.97	13.29	27.33	26.49
Prepaid Expenses	-	1.93	1.18	1.13	-	-
Restricted Cash	-	-	-	-	-	0.34
Other Current Assets	42.97	16.9	2.66	2.27	4.67	3.48
Total Current Assets	309.32	331.56	237.43	263.6	464.75	500.56
Property, Plant & Equipment	10.49	24.81	25.06	27.49	32.6	37.17
Long-Term Investments	10.91	10.91	49.32	3	-	-
Goodwill	-	105.25	103.37	105.67	105.67	189.66
Other Intangible Assets	359.93	266.65	299.61	352.64	386.8	606.31
Long-Term Accounts Receivable	188.32	185.02	62.29	-	-	-
Long-Term Deferred Tax Assets	0.55	0.07	0.21	8.53	35.73	24.32
Other Long-Term Assets	25.92	17.51	9.92	1.74	272.03	4.27
Total Assets	905.44	941.77	787.22	762.67	1,298	1,362
Accounts Payable	28.9	5.23	2.43	5.31	8.4	3.78
Accrued Expenses	-	25.53	10.09	13.3	12.4	15.61
Current Portion of Long-Term Debt	-	-	-	76.7	-	-
Current Portion of Leases	0.88	1.29	0.41	0.72	1.41	8.48
Current Income Taxes Payable	1.8	1.2	-	-	-	-
Current Unearned Revenue	0.1	1.28	1.22	0.36	0.65	29.44
Other Current Liabilities	26.99	2.58	2.63	2.43	18.8	42.8
Total Current Liabilities	58.68	37.11	16.78	98.81	41.67	100.11
Long-Term Debt	-	-	-	-	320.72	442.29
Long-Term Leases	3.57	5.86	5.77	10.34	2.31	5.76
Long-Term Unearned Revenue	-	18.18	15.14	0.04	-	-
Long-Term Deferred Tax Liabilities	29.38	32.52	31.62	30.62	30.86	64.6
Other Long-Term Liabilities	18.27	17.65	16.98	25.37	80.88	40
Total Liabilities	109.9	111.34	86.3	165.18	476.43	652.76
Common Stock	795.53	0.02	0.02	0.02	0.02	0.02
Additional Paid-In Capital	-	337.38	198.7	147.59	372.97	318.36
Retained Earnings	-	498.98	503.02	450.86	449.09	391.95
Comprehensive Income & Other	-	-5.94	-0.82	-0.98	-0.92	-0.8
Total Common Equity	795.53	830.44	700.91	597.49	821.16	709.53
Shareholders' Equity	795.53	830.44	700.91	597.49	821.16	709.53
Total Liabilities & Equity	905.44	941.77	787.22	762.67	1,298	1,362
Total Debt	4.45	7.15	6.18	87.75	324.44	456.53
Net Cash (Debt)	204.45	249.01	164.13	124.12	16.66	-45.34
Net Cash Growth	-32.83%	51.72%	32.23%	644.83%	-	-
Net Cash Per Share	10.96	13.61	9.24	7.36	0.97	-2.69
Filing Date Shares Outstanding	19.19	19.26	17.71	17.08	16.85	16.61
Total Common Shares Outstanding	19.19	19.11	17.56	16.95	16.77	16.08
Working Capital	250.63	294.45	220.65	164.79	423.09	400.45
Book Value Per Share	41.45	43.46	39.92	35.25	48.97	44.13
Tangible Book Value	435.6	458.54	297.94	139.18	328.69	-86.45
Tangible Book Value Per Share	22.70	24.00	16.97	8.21	19.60	-5.38
Machinery	-	8.72	7.78	15.16	14.34	15.72
Construction In Progress	-	4.22	4.12	-	-	-
Leasehold Improvements	-	10.46	10.36	7.45	5.27	3.52

Updated May 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q